TY - JOUR
T1 - Probiotics in Prevention and Treatment of COVID-19
T2 - Current Perspective and Future Prospects
AU - Kurian, Shilia Jacob
AU - Unnikrishnan, Mazhuvancherry Kesavan
AU - Miraj, Sonal Sekhar
AU - Bagchi, Debasis
AU - Banerjee, Mithu
AU - Reddy, B. Shrikar
AU - Rodrigues, Gabriel Sunil
AU - Manu, Mohan K.
AU - Saravu, Kavitha
AU - Mukhopadhyay, Chiranjay
AU - Rao, Mahadev
N1 - Funding Information:
The authors express their gratitude to Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal for the support and facilities. The first author is thankful to Dr. TMA Pai Ph.D. scholarship program, MAHE, Manipal. The authors report no conflicts of interest, Dr.Shilia Jacob Kurian and Dr.Sonal Sekhar Miraj conducted the literature search and wrote the manuscript. Dr. B Shrikar Reddy drew the figure I. Dr. Mazhuvancheny Kesavan Unnikrishnan, Dr. Debasis Bagchi, Dr. Mithu Banerjce. Dr. Gabriel Sunil Rodrigues, Dr. Mohan K Manu, Dr. Kavitha Saravu, Dr. Chiranjay Mukhopadhyay and Dr. Mahadev Rao critically evaluated the manuscript. All the authors participated in literature collection and review. All the authors approved the final draft of the manuscript.
Publisher Copyright:
© 2021 Instituto Mexicano del Seguro Social (IMSS)
PY - 2021/8
Y1 - 2021/8
N2 - Saving lives and flattening the curve are the foremost priorities during the ongoing pandemic spread of SARS-CoV-2. Developing cutting-edge technology and collating available evidence would support frontline health teams. Nutritional adequacy improves general health and immunity to prevent and assuage infections. This review aims to outline the potential role of probiotics in fighting the COVID-19 by covering recent evidence on the association between microbiota, probiotics, and COVID-19, the role of probiotics as an immune-modulator and antiviral agent. The high basic reproduction number (R0) of SARS-CoV-2, absence of conclusive remedies, and the pleiotropic effect of probiotics in fighting influenza and other coronaviruses together favour probiotics supplements. However, further support from preclinical and clinical studies and reviews outlining the role of probiotics in COVID-19 are critical. Results are awaited from many ongoing clinical trials investigating the benefits of probiotics in COVID-19.
AB - Saving lives and flattening the curve are the foremost priorities during the ongoing pandemic spread of SARS-CoV-2. Developing cutting-edge technology and collating available evidence would support frontline health teams. Nutritional adequacy improves general health and immunity to prevent and assuage infections. This review aims to outline the potential role of probiotics in fighting the COVID-19 by covering recent evidence on the association between microbiota, probiotics, and COVID-19, the role of probiotics as an immune-modulator and antiviral agent. The high basic reproduction number (R0) of SARS-CoV-2, absence of conclusive remedies, and the pleiotropic effect of probiotics in fighting influenza and other coronaviruses together favour probiotics supplements. However, further support from preclinical and clinical studies and reviews outlining the role of probiotics in COVID-19 are critical. Results are awaited from many ongoing clinical trials investigating the benefits of probiotics in COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85106238051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106238051&partnerID=8YFLogxK
U2 - 10.1016/j.arcmed.2021.03.002
DO - 10.1016/j.arcmed.2021.03.002
M3 - Review article
C2 - 33785208
AN - SCOPUS:85106238051
SN - 0188-4409
VL - 52
SP - 582
EP - 594
JO - Archives of Medical Research
JF - Archives of Medical Research
IS - 6
ER -